Structural organization and sequence of CLN2, the defective gene in classical late infantile neuronal ceroid lipofuscinosis

被引:51
|
作者
Liu, CG
Sleat, DE
Donnelly, RJ
Lobel, P [1 ]
机构
[1] Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
[3] Univ Med & Dent New Jersey, New Jersey Med Sch, Lab Med & Pathol, Mol Biocore Facil, Newark, NJ 07103 USA
关键词
D O I
10.1006/geno.1998.5328
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Mutations in the CLN2 gene result in classical late infantile neuronal ceroid Iipofuscinosis (LINCL), a fatal childhood neurodegenerative disease. In this report, we present the complete sequence of the human CLN2 gene and define its physical relationship with two other genes that have been previously mapped to chromosome 11p15. The CLN2 gene consists of 13 exons and 12 introns and spans 6.65 kh. By SP mapping and primer extension, the 5'-terminus of the CLN2 mRNA was mapped to 32 nucleotides upstream of the proposed initiation codon. A number of other elements were found to be located in close proximity to CLN2, including the gene encoding transcription factor TAF(II)30, the gene encoding intregrin-linked kinase, and an similar to 914-bp fragment that is 82% identical to antithrombin III. In addition, an EST cDNA clone that is transcribed on the strand opposite to CLN2 and that overlaps a portion of the CLN2 gene was-identified. Finally, a set of primer pairs are presented for the amplification of the coding sequences, putative promoter, and splice junctions of the CLN2 gene. Taken together, this information will facilitate the molecular analysis of and genetic testing for classical LINCL. (C) 1998 Academic Press.
引用
收藏
页码:206 / 212
页数:7
相关论文
共 50 条
  • [41] An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy
    Dorothy A. Thompson
    Siân E. Handley
    Robert H. Henderson
    Oliver R. Marmoy
    Paul Gissen
    Eye, 2021, 35 : 2438 - 2448
  • [42] Second Generation Gene Therapy Vector for Classical Late Infantile Neuronal Ceroid Lipofuscinosis
    Cabrera-Salazar, Mario A.
    Hodges, Bradley L.
    Yew, Nelson S.
    Bu, Jie
    Fidler, Jonathan A.
    Roskelley, Eric M.
    Scheule, Ronald K.
    Sleat, David E.
    Lobel, Peter
    Cheng, Seng H.
    Passini, Marco A.
    MOLECULAR THERAPY, 2006, 13 : S344 - S344
  • [43] LINKAGE ANALYSIS OF LATE-INFANTILE NEURONAL CEROID-LIPOFUSCINOSIS (CLN2) USING MARKERS ON CHROMOSOME-16P
    WILLIAMS, R
    MITCHISON, H
    MCKAY, T
    JARVELA, I
    GARDINER, RM
    JOURNAL OF INHERITED METABOLIC DISEASE, 1993, 16 (02) : 342 - 344
  • [44] INFANTILE NEURONAL CEROID LIPOFUSCINOSIS (CLN1) - LINKAGE DISEQUILIBRIUM IN THE FINNISH POPULATION AND EVIDENCE THAT VARIANT LATE INFANTILE FORM (VARIANT CLN2) REPRESENTS A NONALLELIC LOCUS
    JARVELA, I
    GENOMICS, 1991, 10 (02) : 333 - 337
  • [45] Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA
    Worgall, Stefan
    Sondhi, Dolan
    Hackett, Neil R.
    Kosofsky, Barry
    Kekatpure, Minal V.
    Neyzi, Nurunisa
    Dyke, Jonathan P.
    Ballon, Douglas
    Heier, Linda
    Greenwald, Bruce M.
    Christos, Paul
    Mazumdar, Madhu
    Souweidane, Mark M.
    Kaplitt, Michael G.
    Crystal, Ronald G.
    HUMAN GENE THERAPY, 2008, 19 (05) : 463 - 474
  • [46] An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy
    Thompson, Dorothy A.
    Handley, Sian E.
    Henderson, Robert H.
    Marmoy, Oliver R.
    Gisson, Paul
    EYE, 2021, 35 (09) : 2438 - 2448
  • [47] Enzyme Replacement Therapy Attenuates Disease Progression in a Canine Model of Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
    Katz, Martin L.
    Coates, Joan R.
    Sibigtroth, Christine M.
    Taylor, Jacob D.
    Carpentier, Melissa
    Young, Whitney M.
    Wininger, Fred A.
    Kennedy, Derek
    Vuillemenot, Brian R.
    O'Neill, Charles A.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2014, 92 (11) : 1591 - 1598
  • [48] A novel granular variant (GROD) form of late infantile neuronal ceroid lipofuscinosis (CLN2) is an infantile form of NCL (CLN1) when biochemically studied.
    Wisniewski, KE
    Becerra, CR
    Hofmann, SL
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (05): : 94 - 94
  • [49] Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study
    Nickel, Miriam
    Simonati, Alessandro
    Jacoby, David
    Lezius, Susanne
    Kilian, Dirk
    Van de Graaf, Benjamin
    Pagovich, Odelya E.
    Kosofsky, Barry
    Yohay, Kaleb
    Downs, Matthew
    Slasor, Peter
    Aiayi, Temitayo
    Crystal, Ronald G.
    Kohlschuetter, Alfried
    Sondhi, Dolan
    Schulz, Angela
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (08): : 582 - 590
  • [50] Novel mutations in the CLN6 gene causing a variant late infantile neuronal ceroid lipofuscinosis
    Teixeira, CA
    Espinola, J
    Huo, L
    Kohlschütter, J
    Sawin, DAP
    Minassian, B
    Bessa, CJP
    Guimaraes, A
    Stephan, DA
    Miranda, MCS
    MacDonald, ME
    Ribeiro, MG
    Boustany, RMN
    HUMAN MUTATION, 2003, 21 (05) : 502 - 508